{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T21:24:17Z","timestamp":1790630657045,"version":"4.1.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"vor","delay-in-days":1461,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1038\/ki.2013.517","type":"journal-article","created":{"date-parts":[[2014,1,8]],"date-time":"2014-01-08T13:46:42Z","timestamp":1389188802000},"page":"1434-1443","source":"Crossref","is-referenced-by-count":45,"title":["Pharmacokinetic modeling of enterohepatic circulation of mycophenolic acid in renal transplant recipients"],"prefix":"10.1016","volume":"85","author":[{"given":"Helena","family":"Colom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N\u00faria","family":"Lloberas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franc","family":"Andreu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Cald\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Torras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Oppenheimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Sanchez-Plumed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel A.","family":"Gentil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk R.","family":"Kuypers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merc\u00e8","family":"Brunet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Ekberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep M.","family":"Griny\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/ki.2013.517_bb0010","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/BF02171743","article-title":"Mychophenolate mofetil: molecular mechanisms of action","volume":"2","author":"Wu","year":"1994","journal-title":"Persp Drug Disc Design"},{"key":"10.1038\/ki.2013.517_bb0015","first-page":"314","article-title":"Inhibition of human B cell responses in vitro by RS-61443, cyclosporine A and DAB486 IL-2","volume":"23","author":"Grailer","year":"1991","journal-title":"Transplant Proc"},{"key":"10.1038\/ki.2013.517_bb0020","first-page":"15","article-title":"Lymphocyte-selective antiproliferative and immunosuppressive activity of mycophenolic acid and its morpholinoethyl ester (RS-61443) in rodents","volume":"23","author":"Eugui","year":"1991","journal-title":"Transplant Proc"},{"key":"10.1038\/ki.2013.517_bb0025","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2165\/00003088-200746010-00002","article-title":"Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients","volume":"46","author":"Staatz","year":"2007","journal-title":"Clin Pharmacokinet"},{"key":"10.1038\/ki.2013.517_bb0030","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1124\/dmd.104.001651","article-title":"Identification of UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism","volume":"33","author":"Picard","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1038\/ki.2013.517_bb0035","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2165\/00003088-199834060-00002","article-title":"Clinical pharmacokinetics of mycophenolate mofetil","volume":"34","author":"Bullingham","year":"1998","journal-title":"Clin Pharmacokinet"},{"key":"10.1038\/ki.2013.517_bb0040","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1124\/dmd.105.006122","article-title":"Role of MRP2 in the hepatic disposition of mycophenolic acid and its glucuronide metabolites: effect of cyclosporine","volume":"34","author":"Westley","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1038\/ki.2013.517_bb0045","first-page":"925","article-title":"Pharmacokinetics of mycophenolate mofetil (RS 61443): A short review","volume":"28","author":"Bullingham","year":"1996","journal-title":"Transplant Proc"},{"key":"10.1038\/ki.2013.517_bb0050","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S1053-2498(00)00289-8","article-title":"Co-administration of tacrolimus and mycophenolate mofetil does not increase mycophenolic acid (MPA) exposure, but co-administration of cyclosporine inhibits the enterohepatic recirculation of MPA, thereby decreasing its exposure","volume":"20","author":"Van Gelder","year":"2001","journal-title":"J Heart Lung Transplant"},{"key":"10.1038\/ki.2013.517_bb0055","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/00007691-200104000-00005","article-title":"Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid","volume":"23","author":"Van Gelder","year":"2001","journal-title":"Ther Drug Monit"},{"key":"10.1038\/ki.2013.517_bb0060","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1124\/jpet.103.063073","article-title":"Cyclosporin A but not tacrolimus inhibits the biliary excretion of mycophenlic acid glucuronide possibly mediated by multidrug resistance-associated protein 2 in rats","volume":"309","author":"Kobayashi","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1038\/ki.2013.517_bb0065","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1046\/j.1600-6143.2005.00779.x","article-title":"Cyclosporine interacts with mycophenolic acid by inhibiting the resistance-associated protein 2","volume":"5","author":"Hessenlink","year":"2005","journal-title":"Am J Transpl"},{"key":"10.1038\/ki.2013.517_bb0070","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1093\/ndt\/gfr130","article-title":"Influence of MRP2 on MPA pharmacokinetics in renal transplant recipients. Results of the pharmacogenomic substudy within the Symphony study","volume":"26","author":"Lloberas","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/ki.2013.517_bb0075","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1681\/ASN.2005101070","article-title":"Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: A population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients","volume":"17","author":"Van Hest","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2013.517_bb0080","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/j.1365-2125.2008.03109.x","article-title":"Population pharmacokinetic modelling for enterohepatic circulation of mycophenolic acid in healthy Chinese and the influence of polymorphisms in UGT1A9","volume":"65","author":"Jiao","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"10.1038\/ki.2013.517_bb0085","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1046\/j.1365-2125.2003.01863.x","article-title":"Population pharmacokinetic analysis of mycophenolic acid in renal transplant recipients following oral administration of mycophenolate mofetil","volume":"56","author":"Shum","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"10.1038\/ki.2013.517_bb0090","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s00228-005-0927-4","article-title":"Population pharmacokinetics of mycophenolic acid during the first week after renal transplantation","volume":"61","author":"Staatz","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1038\/ki.2013.517_bb0095","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2165\/00003088-200544100-00006","article-title":"Population pharmacokinetics of mycophenolic acid in renal trasnplant recipients","volume":"44","author":"Van Hest","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1038\/ki.2013.517_bb0100","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/01.ftd.0000159784.25872.f6","article-title":"Population pharmacokinetics of mycophenolic acid in kidney transplant pediatric and adolescent patients","volume":"27","author":"Payen","year":"2005","journal-title":"Ther Drug Monit"},{"key":"10.1038\/ki.2013.517_bb0105","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/j.1365-2125.2006.02841.x","article-title":"Time-dependent clearance of mycophenolic acid in renal transplant recipients","volume":"63","author":"Van Hest","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"10.1038\/ki.2013.517_bb0110","doi-asserted-by":"crossref","first-page":"827","DOI":"10.2165\/0003088-200847120-00007","article-title":"Population pharmacokinetics of Mycophenolic acid: A comparison between enteric-coated mycophenolate sodium and mycophenolate mofetil in renal transplant recipients","volume":"47","author":"De Winter","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"10.1038\/ki.2013.517_bb0115","doi-asserted-by":"crossref","first-page":"464","DOI":"10.2165\/11312600-000000000-00000","article-title":"Pharmacokinetic modelling of the plasma protein binding of mycophenolic acid in renal transplant recipients","volume":"48","author":"Van Hest","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"10.1038\/ki.2013.517_bb0120","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s10928-009-9136-6","article-title":"Phamacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients","volume":"36","author":"De Winter","year":"2009","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1038\/ki.2013.517_bb0125","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/FTD.0b013e3181e6b54d","article-title":"Population pharmacokinetics analysis of mycophenolic acid in adult kidney transplant patients with chronic graft function","volume":"32","author":"Guillet","year":"2010","journal-title":"Ther Drug Monit"},{"key":"10.1038\/ki.2013.517_bb0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/11536640-000000000-00000","article-title":"The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease","volume":"50","author":"Sherwin","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"10.1038\/ki.2013.517_bb0135","doi-asserted-by":"crossref","first-page":"745","DOI":"10.2165\/11318060-000000000-00000","article-title":"Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus","volume":"48","author":"Musuamba","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"10.1038\/ki.2013.517_bb0140","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s10928-007-9066-0","article-title":"Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies","volume":"34","author":"Savic","year":"2007","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1038\/ki.2013.517_bb0145","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/BF01113502","article-title":"The importance of modeling interoccasion variability in population pharmacokinetic analyses","volume":"21","author":"Karlsson","year":"1993","journal-title":"J Pharmacokinet Biopharm"},{"key":"10.1038\/ki.2013.517_bb0150","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1208\/s12248-009-9133-0","article-title":"Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions","volume":"11","author":"Savic","year":"2009","journal-title":"AAPS J"},{"key":"10.1038\/ki.2013.517_bb0155","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1007\/s11095-007-9361-x","article-title":"Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method","volume":"24","author":"Hooker","year":"2007","journal-title":"Pharm Res"},{"key":"10.1038\/ki.2013.517_bb0160","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s10928-005-0016-4","article-title":"Prediction discrepancies for the evaluation of nonlinear mixed-effects models","volume":"33","author":"Mentr\u00e9","year":"2006","journal-title":"J Pharmacokinet Biopharm"},{"key":"10.1038\/ki.2013.517_bb0165","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","article-title":"Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models","volume":"13","author":"Bergstrand","year":"2011","journal-title":"AAP J"},{"key":"10.1038\/ki.2013.517_bb0170","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1023\/A:1011555016423","article-title":"Evaluating pharmacokinetic-pharmacodynamic models using the posterior predictive check","volume":"28","author":"Yano","year":"2001","journal-title":"J Pharmacokinet Biopharm"},{"key":"10.1038\/ki.2013.517_bb0175","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/0091270008329558","article-title":"Population pharmacokinetics of mycophenolic acid and its 2 glucuronidated metabolites in kidney transplant recipients","volume":"49","author":"Sam","year":"2009","journal-title":"J Clin Pharmacol"},{"key":"10.1038\/ki.2013.517_bb0180","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1046\/j.0306-5251.2001.01487.x","article-title":"The glucuronidation of mycophenolic acid by human liver, kidney and jejunum microsomes","volume":"52","author":"Bowalgaha","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"10.1038\/ki.2013.517_bb0185","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1067\/mcp.2002.121829","article-title":"Changes in plasma protein binding have little clinical relevance","volume":"71","author":"Benet","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"10.1038\/ki.2013.517_bb0190","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/00007691-200206000-00011","article-title":"Pharmacokinetic and protein adduct formation of the pharmacologically active acyl glucuronide metabolite of mycophenolic acid in pediatric renal transplant recipients","volume":"24","author":"Shipkova","year":"2002","journal-title":"Ther Drug Monit"},{"key":"10.1038\/ki.2013.517_bb0195","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/FTD.0b013e318180c709","article-title":"AcylMPAG plasma concentrations and mycophenolic acid-related side effects in patients undergoing renal transplantation are not related to the UGT2B7-840G>A gene polymorphism","volume":"30","author":"Agteren","year":"2008","journal-title":"Ther Drug Monit"},{"key":"10.1038\/ki.2013.517_bb0200","first-page":"73","article-title":"The impact of renal allograft function on exposure and elimination of mycophenolic acid (MPA) and its metabolite MPA 7-O-glucuronide. Transplantation","volume":"3","author":"Naesens","year":"2007","journal-title":"84"},{"key":"10.1038\/ki.2013.517_bb0205","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1093\/ndt\/gfp162","article-title":"The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low dose cyclosporine, low dose tacrolimus or low-dose sirolimus: the Symphony pharmacokinetic substudy","volume":"24","author":"Griny\u00f3","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/ki.2013.517_bb0210","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1681\/ASN.V981511","article-title":"Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients","volume":"9","author":"Weber","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2013.517_bb0215","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1681\/ASN.V133759","article-title":"Pharmacokinetic- pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: a report of the german group on mycophenolate mofetil therapy","volume":"13","author":"Weber","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2013.517_bb0220","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1056\/NEJMoa067411","article-title":"Reduced Exposure to Calcineurin Inhibitors in Renal Transplantation","volume":"357","author":"Ekberg","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2013.517_bb0225","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/01.tp.0000200307.79962.48","article-title":"Sequential determination of pharmacokinetics and pharmacodynamics of mycophenolic acid in liver transplant patients treated with mycophenolate mofetil","volume":"81","author":"Brunet","year":"2006","journal-title":"Transplantation"},{"key":"10.1038\/ki.2013.517_bb0230","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/BF03256246","article-title":"T cell function monitoring in stable renal transplant patients treated with sirolimus monotherapy","volume":"11","author":"Brunet","year":"2007","journal-title":"Mol Diagn Ther"},{"key":"10.1038\/ki.2013.517_bb0235","series-title":"Icon Development Solutions: Ellicot City, Maryland","article-title":"NONMEM User\u2019s guide","author":"Bauer","year":"2011"},{"key":"10.1038\/ki.2013.517_bb0240","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0169-2607(98)00067-4","article-title":"Xpose: an S-PLUS based population pharmacokinetic\/pharmacodynamic model building aid for NONMEM","volume":"58","author":"Jonsson","year":"1999","journal-title":"Comput Methods Programs Biomed"},{"key":"10.1038\/ki.2013.517_bb0245","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.cmpb.2005.04.005","article-title":"PsN-Toolkit: a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM","volume":"79","author":"Lindbom","year":"2005","journal-title":"Comput Methods Programs Biomed"},{"key":"10.1038\/ki.2013.517_bb0250","unstructured":"The R project for statistical computing http:\/\/cran.es.r-project.org\/"},{"key":"10.1038\/ki.2013.517_bb0255","unstructured":"WinNonlin Professional ver 5.3. Pharsight Corporation 1998-2009"},{"key":"10.1038\/ki.2013.517_bb0260","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/BF01117450","article-title":"Application of Akaike\u2019s Information Criterion (AIC) in the evaluation of linear pharmacokinetics equations","volume":"6","author":"Yamaoka","year":"1978","journal-title":"J Pharmacokinet Biopharm"},{"key":"10.1038\/ki.2013.517_bb0265","article-title":"The Visual Predictive Check \u2013 Superiority to Standard Diagnostic (Rorschach) Plots","author":"Holford","year":"2005"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815563680?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815563680?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T22:42:03Z","timestamp":1647902523000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253815563680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":52,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S0085253815563680"],"URL":"https:\/\/doi.org\/10.1038\/ki.2013.517","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]}}}